Sargent Investment Group LLC Has $553,000 Stock Holdings in Matinas BioPharma Holdings, Inc. (NYSEAMERICAN:MTNB)

Posted by Thomas Dobrow on Sep 17th, 2024

Sargent Investment Group LLC lowered its stake in Matinas BioPharma Holdings, Inc. (NYSEAMERICAN:MTNB – Free Report) by 3.3% during the second quarter, according to the company in its most recent filing with the SEC. The fund owned 3,492,000 shares of the company’s stock after selling 118,500 shares during the period. Sargent Investment Group LLC’s holdings in Matinas BioPharma were worth $553,000 as of its most recent filing with the SEC.

Other large investors have also recently bought and sold shares of the company. Private Advisor Group LLC grew its holdings in Matinas BioPharma by 31.1% in the 4th quarter. Private Advisor Group LLC now owns 337,330 shares of the company’s stock valued at $73,000 after buying an additional 80,000 shares in the last quarter. Alliance Wealth Management Group bought a new stake in shares of Matinas BioPharma in the second quarter valued at about $299,000. Finally, Towercrest Capital Management acquired a new position in shares of Matinas BioPharma in the second quarter valued at about $299,000. 11.77% of the stock is owned by institutional investors.

Matinas BioPharma Stock Down 3.4 %

Shares of Matinas BioPharma stock opened at $3.71 on Tuesday. Matinas BioPharma Holdings, Inc. has a twelve month low of $3.28 and a twelve month high of $44.50. The stock has a market capitalization of $18.62 million, a price-to-earnings ratio of -30.92 and a beta of 1.65.

Matinas BioPharma (NYSEAMERICAN:MTNB – Get Free Report) last issued its quarterly earnings results on Wednesday, August 14th. The company reported ($0.02) earnings per share (EPS) for the quarter, meeting the consensus estimate of ($0.02).

Matinas BioPharma Company Profile

(Free Report)

Matinas BioPharma Holdings, Inc, a clinical-stage biopharmaceutical company, identifies and develops pharmaceutical products using its lipid nanocrystal (LNC) platform technology. The company's LNC delivery technology platform utilizes lipid nanocrystals for the delivery of small molecules, nucleic acids, gene therapies, vaccines, proteins, and peptides.